Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Parkinson's Disease

Free Subscription 16.05.2022 2 BMC Neurol 1 Int J Neurosci 2 J Neural Transm (Vienna) 5 Mov Disord 2 Nat Neurosci 1 Neurobiol Dis 1 Neurochem Res 1 Neurologia (Engl Ed) 1 Neurosci Lett 1 PLoS Comput Biol 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. TERRENS AF, Soh SE, Morgan P
   What web-based information is available for people with Parkinson's disease interested in aquatic physiotherapy? A social listening study.
   BMC Neurol. 2022;22:170.
   PubMed         Abstract available
   
   
2. VISMARA M, Benatti B, Nicolini G, Cova I, et al
   Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.
   BMC Neurol. 2022;22:169.
   PubMed         Abstract available
   
   

   
   Int J Neurosci

3. ATHARI SZ, Farajdokht F, Sadigh Eteghad S, Mohajeri D, et al
   Hydroxychloroquine attenuated motor impairment and oxidative stress in a rat 6-hydroxydopamine model of Parkinson's disease.
   Int J Neurosci. 2022 May 6:1-13. doi: 10.1080/00207454.2022.2074848.
   PubMed         Abstract available
   
   

   
   J Neural Transm (Vienna)

4. FALKENBURGER B, Kalliakoudas T, Reichmann H
   Adaptive changes in striatal projection neurons explain the long duration response and the emergence of dyskinesias in patients with Parkinson's disease.
   J Neural Transm (Vienna). 2022 May 10. pii: 10.1007/s00702-022-02510.
   PubMed         Abstract available
   
   
5. FOLEY PB, Hare DJ, Double KL
   A brief history of brain iron accumulation in Parkinson disease and related disorders.
   J Neural Transm (Vienna). 2022 May 9. pii: 10.1007/s00702-022-02505.
   PubMed         Abstract available
   
   

   
   Mov Disord

6. FILIPPI M, Balestrino R, Basaia S, Agosta F, et al
   Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
   Mov Disord. 2022 May 6. doi: 10.1002/mds.29047.
   PubMed         Abstract available
   
   
7. PAN Y, Xue J, Chen J, Zhang X, et al
   Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease.
   Mov Disord. 2022 May 6. doi: 10.1002/mds.29041.
   PubMed        
   
   
8. WANG S, Unnithan S, Bryant N, Chang A, et al
   Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
   Mov Disord. 2022 May 6. doi: 10.1002/mds.29043.
   PubMed         Abstract available
   
   
9. SOSSI V, Patterson JR, McCormick S, Kemp CJ, et al
   Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.
   Mov Disord. 2022 May 7. doi: 10.1002/mds.29051.
   PubMed         Abstract available
   
   
10. YAMASHITA R, Beck G, Yonenobu Y, Inoue K, et al
    TDP-43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease.
    Mov Disord. 2022 May 9. doi: 10.1002/mds.29048.
    PubMed         Abstract available
    
    

    
    Nat Neurosci

11. ARENAS E
    Parkinson's disease in the single-cell era.
    Nat Neurosci. 2022;25:536-538.
    PubMed        
    
    
12. KAMATH T, Abdulraouf A, Burris SJ, Langlieb J, et al
    Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease.
    Nat Neurosci. 2022;25:588-595.
    PubMed         Abstract available
    
    

    
    Neurobiol Dis

13. BARTL M, Xylaki M, Bahr M, Weber S, et al
    Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease.
    Neurobiol Dis. 2022 May 2:105744. doi: 10.1016/j.nbd.2022.105744.
    PubMed         Abstract available
    
    

    
    Neurochem Res

14. ADEBAYO OG, Aduema W, Emmanuel MU, Ben-Azu B, et al
    The Anti-Parkinson Potential of Gingko biloba-Supplement Mitigates Cortico-Cerebellar Degeneration and Neuropathobiological Alterations via Inflammatory and Apoptotic Mediators in Mice.
    Neurochem Res. 2022 May 9. pii: 10.1007/s11064-022-03600.
    PubMed         Abstract available
    
    

    
    Neurologia (Engl Ed)

15. BAVIERA-MUNOZ R, Buigues-Lafuente A, Campins-Romeu M, Garces-Sanchez M, et al
    Refractory status epilepticus due to vitamin B6 deficit in a Parkinson's disease patient in treatment with levodopa/carbidopa intestinal gel.
    Neurologia (Engl Ed). 2022 May 5. pii: S2173-5808(22)00047.
    PubMed        
    
    

    
    Neurosci Lett

16. SHKODINA AD, Tarianyk KA, Boiko DI, Zehravi M, et al
    Cognitive and affective disturbances in patients with Parkinson's disease: perspectives for classifying of motor/neuropsychiatric subtypes.
    Neurosci Lett. 2022 May 6:136675. doi: 10.1016/j.neulet.2022.136675.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

17. HEZEMANS FH, Wolpe N, O'Callaghan C, Ye R, et al
    Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.
    PLoS Comput Biol. 2022;18:e1010079.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

18. HOROWITZ T, Grimaldi S, Azulay JP, Guedj E, et al
    Molecular imaging in Parkinsonism: The essential for clinical practice and future perspectives.
    Rev Neurol (Paris). 2022 May 5. pii: S0035-3787(22)00547.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: